Diarrhoea News and Research RSS Feed - Diarrhoea News and Research

HRQoL benefit of alternative sunitinib dosing schedule in RCC patients

HRQoL benefit of alternative sunitinib dosing schedule in RCC patients

Patients with metastatic renal cell carcinoma reported a marked improvement in their health-related quality of life when given sunitinib on a 2 weeks on and 1 week off schedule compared with a 4 weeks on and 2 weeks off regimen, a Japanese study finds. [More]
Study: Blood test can help identify bowel cancer patients who may benefit from chemotherapy

Study: Blood test can help identify bowel cancer patients who may benefit from chemotherapy

Manchester researchers have provided early evidence to suggest that a blood test could be used to identify bowel cancer patients that may benefit from more intensive chemotherapy. [More]
Fourth-line bosutinib ‘appropriate’ after prior CML treatment failure, intolerance

Fourth-line bosutinib ‘appropriate’ after prior CML treatment failure, intolerance

A Spanish study suggests that bosutinib can help improve or maintain response in patients with chronic myeloid leukaemia after treatment failure of three previous tyrosine kinase inhibitors. [More]
New analysis of medieval cesspit in Jerusalem provides window into spread of infectious diseases

New analysis of medieval cesspit in Jerusalem provides window into spread of infectious diseases

A new analysis of a medieval cesspit in the Christian quarter of the old city of Jerusalem has revealed the presence of a number of ancient parasite eggs, providing a window into the nature and spread of infectious diseases in the Middle East during the 15th century. [More]
WHO calls for intensification of routine immunization services in all Ebola-affected areas

WHO calls for intensification of routine immunization services in all Ebola-affected areas

A growing risk of outbreaks of measles, pertussis, and other vaccine-preventable diseases in countries affected by Ebola must be countered by urgent scaling up of routine immunization activities, according to the World Health Organization. [More]
Medical experts aim to offer lifesaving treatments to eliminate preventable deaths from AKI by 2025

Medical experts aim to offer lifesaving treatments to eliminate preventable deaths from AKI by 2025

Preventable deaths caused by acute kidney injury (AKI) could be nearly eliminated in just 10 years, according to leading medical experts. This often forgotten condition - which affects around 13 million people every year and contributes to 1.7 million deaths annually - is preventable and can be treated for as little as $US150 per patient. [More]
Bielefeld University chemists develop copper molecule that could help prevent spread of cancer

Bielefeld University chemists develop copper molecule that could help prevent spread of cancer

Chemists at Bielefeld University have developed a molecule containing copper that binds specifically with DNA and prevents the spread of cancer. First results show that it kills the cancer cells more quickly than cisplatin - a widely used anti-cancer drug that is frequently administered in chemotherapy. [More]
Study may give health workers vital new evidence in fight against Ebola

Study may give health workers vital new evidence in fight against Ebola

One year after the first Ebola cases started to surface in Guinea, the latest findings from a Cochrane review show new ways of hydrating patients in critical care environments across the world. [More]
Second-line bosutinib well tolerated by Japanese patients

Second-line bosutinib well tolerated by Japanese patients

Phase I/II clinical trial data support the use of bosutinib as second- or third-line tyrosine kinase inhibitor therapy in Japanese patients with Philadelphia chromosome-positive chronic myeloid leukaemia. [More]
Antibiotic use by travellers may promote spread of drug-resistant 'super-bacteria'

Antibiotic use by travellers may promote spread of drug-resistant 'super-bacteria'

Treating travellers' diarrhoea with antibiotics can promote the spread of drug-resistant "super-bacteria". [More]

LUME-Lung 1 shows QoL, symptoms benefits

LUME-Lung 1 trial patients’ reports of symptoms and health-related quality of life support the use of second-line nintedanib for the treatment of advanced non-small-cell lung cancer. [More]
Amrubicin, carboplatin duo efficacious in thymic carcinoma, not invasive thymoma

Amrubicin, carboplatin duo efficacious in thymic carcinoma, not invasive thymoma

Combination therapy with amrubicin and carboplatin is moderately effective in patients with advanced thymic carcinoma, a Japanese study finds, but invasive thymoma patients do not benefit from this regimen. [More]
British scientists take major initiative to tackle Crohn's disease

British scientists take major initiative to tackle Crohn's disease

British scientists are playing a key role in a global quest to find the causes of an incurable bowel condition. [More]

Elsevier launches new virtual journal: Atlas

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the launch of a new virtual journal: Atlas. Published as a virtual journal, Atlas selects already published research on topics that hold high societal relevance or address global issues, and summarizes and presents the science in a lay-friendly, story format to reach an as wide as possible global audience. [More]

Long-term axitinib in RCC effective with ‘controllable’ toxicities

Axitinib treatment is effective in the long-term in Japanese patients with metastatic renal cell carcinoma and has manageable toxicity, a phase II study suggests. [More]
New analysis finds global improvements in life expectancy

New analysis finds global improvements in life expectancy

Global life expectancy increased by 5.8 years in men and 6.6 years in women between 1990 and 2013, according to a major new analysis from the Global Burden of Disease Study 2013 (GBD 2013). [More]
Figitumumab development discontinued for non-adenocarcinoma NSCLC

Figitumumab development discontinued for non-adenocarcinoma NSCLC

Adding the novel insulin-like growth factor 1 receptor inhibitor figitumumab to the epidermal growth factor receptor–tyrosine kinase inhibitor erlotinib does not improve survival in patients with non-adenocarcinoma non-small-cell lung carcinoma, research shows. [More]
First-line dacomitinib may improve advanced NSCLC survival

First-line dacomitinib may improve advanced NSCLC survival

Preliminary research suggests that the second-generation tyrosine kinase inhibitor dacomitinib may improve progression-free survival in patients with advanced non-small-cell lung cancer with epidermal growth factor receptor mutations. [More]

Study indicates major added benefit of propranolol in some children with haemangioma

The Institute for Quality and Efficiency in Health Care (IQWiG)investigated in a dossier assessment whether propranolol offers an added benefit in comparison with the appropriate comparator therapy in infants with proliferating infantile haemangioma (sometimes called "strawberry mark"). [More]
Simple treatments for Ebola patients not given sufficient priority

Simple treatments for Ebola patients not given sufficient priority

The widespread misconception that there are no proven treatments for Ebola virus disease has meant that simple treatments – especially intravenous fluids and electrolytes, which could reduce the number of deaths caused by the virus – have been neglected, according to a new Comment, published in The Lancet. [More]
Advertisement
Advertisement